TS-037747 —
A novel peptide therapeutic AAC2 comprising amino acids with a coumarin-modified side chain that improves glucose control and reduces neurological decline and anxiety through activation of the insulin-insensitive glucose transporter 1 (GLUT1).
A national study done in 2016 on US adults with diabetes estimated that 0.5% of the population was diagnosed with type 1 diabetes (T1D) (~1.6 million) and 8.5% was diagnosed with type 2 diabetes (T2D) (~27 million). Globally there are ~415 million adults living with diabetes in 2015, with a projec…
